Oregon pioneered legal psilocybin therapy, but service-center closures, high costs, and proposed fee hikes are testing whether the supervised-use model can survive as a business.
Key Takeaways
- The pioneer market is contracting: Oregon legalized supervised psilocybin use in 2020, but roughly a third to half of its licensed service centers have since closed or surrendered their licenses. The model’s clinical promise has outrun its business viability.
- The economics do not work for most clients: Sessions commonly run from about $850 to $3,000 and are not covered by insurance, so access has skewed toward wealthier clients. The price reflects the hours of supervision the model requires.
- Regulators are raising fees to survive: Oregon has proposed doubling annual license fees to sustain the program, which operators warn could force more closures. The regulatory cost structure is itself part of the viability problem.
- Other states are testing different designs: Colorado built a lower-friction model and New Mexico a medical one requiring a diagnosis, each an experiment in fixing what Oregon exposed. The question is whether any design makes the business sustainable.
When Oregon voters approved legal psilocybin therapy in 2020, the vote was widely read as a glimpse of the future of mental health care. The clinical research on psilocybin, the psychoactive compound in what are colloquially called magic mushrooms, had been genuinely promising for depression and other conditions, and Oregon was building the country’s first regulated system for supervised adult use, a model that would let a person undergo a psilocybin session with a trained facilitator in a licensed center. It looked like the leading edge of a new therapeutic industry. Six years later, the leading edge looks considerably more precarious, and the reason has less to do with the medicine than with the math.
Oregon’s psilocybin experiment has become a real-world stress test of whether supervised psychedelic therapy can survive as a business, and the early results are sobering. Service centers have closed faster than new ones have opened, the price of a session has kept the treatment out of reach for most people, and the state’s own regulators, facing a program that has not generated enough revenue to sustain itself, have proposed raising fees in a way that operators warn will only accelerate the closures. For an industry watched closely as a bellwether for psychedelic medicine, the Oregon story is a caution about the distance between clinical promise and a working business model.
How the Pioneer Market Contracted
Clearest sign of trouble is the count of centers themselves. Oregon has licensed 39 psilocybin service centers, and about half of those licenses have since expired or been surrendered, a striking attrition rate for an industry only a few years into operation. Separate reporting has found that roughly a third of the service centers that opened have closed, and the closures have hit even operators who appeared to be meeting or exceeding expected client volume. The pattern is not a handful of poorly run businesses failing; it is a structural difficulty that has reached across the industry.
Stories behind individual closures point to the same underlying problem. One Portland center shut down after five months when its investor abruptly withdrew funding, having concluded the business was not viable, even though the operator said the center was matching its competitors’ client numbers. Oregon’s program has served an estimated 22,000 people since centers opened in 2023, a real number that nonetheless has not translated into enough sustained business to keep the licensed centers open, which is the central puzzle of Oregon’s experiment: genuine demand and genuine clinical interest have not added up to a durable industry.
Why the Economics Are So Hard
At its core, supervised psilocybin therapy is expensive to deliver and expensive to buy, and nothing bridges the gap between the two. A single session commonly costs between about $850 and $3,000, a price that reflects what the model actually requires, since a psilocybin session involves hours of one-on-one supervision by a trained facilitator, plus preparation and integration sessions around it, a labor-intensive structure with little room for the efficiencies that bring down the cost of other treatments. The upshot is a service priced like a luxury, which has meant, as advocates acknowledge, that clients have skewed white and wealthier, a real equity problem and a limit on the size of the market.
The operating model compounds the cost problem. A service center earns revenue only when a facilitator is sitting with a client through a multi-hour session, a fundamentally unscalable unit of production, and the facilitators themselves must be licensed and trained, adding a workforce cost on top of the real estate, the product testing, and the compliance overhead. Some operators have argued that the industry priced itself unrealistically, imagining a premium wellness experience where a more modest and affordable one might have found a wider market, but even the leaner operators run into the same arithmetic: the hours of supervision are the product, and hours do not get cheaper with volume the way pills or software do.
Insurance does not help, and largely cannot. Because psilocybin remains federally illegal, the regulated state programs operate outside the health-insurance system entirely, so every session is paid out of pocket, and the businesses face the same banking and financial friction that has long dogged state-legal cannabis. There is no reimbursement stream to build a practice on, none of the payer architecture that sustains the rest of behavioral health, and the familiar gap between a promising intervention and a payment system willing to fund it is, in the psilocybin market, close to absolute. A business model that depends entirely on wealthy clients paying cash for a costly, time-intensive service is a fragile one, and the closures have borne that out.
The Regulatory Cost Problem
Compounding all of this is the cost of the regulation itself, which has become its own flashpoint. In late June 2026, the Oregon Health Authority proposed steep fee increases across the industry, including doubling the annual license fee for service centers and manufacturers from $10,000 to $20,000. Its rationale was financial: the program was designed to be self-sustaining on licensing fees, but slow growth meant it had not generated enough revenue to cover its own regulatory costs, so the state proposed asking the surviving businesses to pay more.
Operators and advocates reacted with alarm, warning that raising costs on an industry already struggling to stay open would push more centers under and drive session prices higher still, deepening the access problem the high costs had already created. One advocate called the proposed increases unprecedented and out of line with the fees charged to comparable businesses. The episode captures the bind Oregon finds itself in: a program that cannot sustain itself on the current fees but may not survive higher ones, a regulatory structure searching for a sustainable footing that the underlying business economics may not be able to support. The state has also begun opening the door to integrating psilocybin with the medical system, a possible path toward legitimacy and, eventually, coverage, but that remains an aspiration rather than a fix.
What Other States and Operators Can Learn
Oregon’s difficulties have become a set of lessons for the states following it, each of which has adjusted the design in response. Colorado, which launched its own regulated program after Oregon, built a lower-friction system with somewhat cheaper licensing and fewer barriers to practices like microdosing, and some Oregon operators have expanded there in search of a more workable environment. New Mexico took a different path altogether, authorizing a medical model that requires a qualifying diagnosis such as PTSD or treatment-resistant depression to access psilocybin, with state health officials targeting their first patients by the end of 2026, a year ahead of the statutory deadline. Each represents a distinct bet about what Oregon got wrong, whether the problem was friction, cost, the absence of a medical framework, or some combination.
For operators and investors weighing the psychedelic space, the Oregon experience is a valuable and cautionary data point rather than a verdict. It demonstrates that clinical promise and even real demand do not guarantee a viable business when the cost of delivery is high, insurance is absent, and the regulatory structure is still finding its shape, the same hard economics that govern much of behavioral health but in an especially unforgiving form. It does not prove that supervised psychedelic therapy cannot work as a business, only that the first attempt has struggled, and that the model’s survival may depend on the lower costs, medical framing, or eventual insurance coverage that other states and a possible federal shift could bring. The future of psychedelic therapy is still being written. Oregon is the cautionary first chapter, and the operators eyeing this space are reading it closely.
